Medicine and Dentistry
Antenatal Corticosteroid
7%
Atosiban
13%
Biochemical Recurrence
8%
Breast Cancer
26%
Cancer Recurrence
6%
Cervical Cerclage
6%
Cervical Length Measurement
50%
Cesarean Section
6%
Clinical Trial
7%
Coronary Artery
7%
Early Labor
14%
Fetus Growth
12%
Fibronectin
10%
Gestational Age
8%
Head and Neck Cancer
34%
Intrauterine Hypoxia
8%
Isotopes of Calcium
6%
Left Ventricle
7%
Multiple Pregnancy
38%
Newborn Death
7%
Newborn Morbidity
7%
Nifedipine
27%
Parotid Gland
13%
Patient Selection
8%
Perinatal Mortality
8%
Pessary
46%
Placebo
17%
Placental Insufficiency
6%
Positron Emission Tomography-Computed Tomography
8%
Predictive Factor
8%
Pregnancy
26%
Premature Labor
100%
Prematurity
9%
Progesterone
7%
Prostate Cancer
13%
Proton Therapy
29%
Radiation Therapy
46%
Randomized Controlled Trial
72%
Relative Biologic Effectiveness
6%
Retrospective Cohort Study
6%
Rupture of Membranes
13%
Second Trimester Pregnancy
13%
Side Effect
14%
Stem Cell
12%
Stillbirth
9%
Surgery
6%
Systematic Review
7%
Tocolysis
21%
Twin Pregnancy
19%
Xerostomia
17%
Keyphrases
17α-hydroxyprogesterone Caproate
6%
Acute Coronary Event
8%
Allopurinol
6%
Androgen Deprivation Therapy
6%
Anti-metastasis
6%
Arrested Preterm Labor
6%
Behavioral Outcomes
6%
Breast Cancer Patients
8%
Cancer Patients
10%
Cardiovascular Risk Prediction
6%
Cervical Cerclage
6%
Cervical Length
8%
Cervical Pessary
6%
Clinical Experience
6%
Comprehensive Toxicity
6%
Coronary Artery Calcium Score
6%
Early Labour
7%
Esophageal Cancer
13%
Female-specific
6%
Fetal Fibronectin
7%
Fetal Hypoxia
6%
Growth Discordance
6%
Head-and-neck Cancer
6%
Labour Assessment
13%
Lung Cancer
6%
Maintenance Tocolysis
14%
Model Performance Measures
6%
Model Selection
13%
National Protocol
6%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Neurodevelopmental Outcome
7%
Nifedipine
13%
Patient Cohort
6%
Perinatal Outcome
13%
Placebo
7%
Prediction Model
8%
Prelabor Rupture of Membranes
6%
Preterm Birth Prediction
6%
Proton
6%
Proton Therapy
14%
Radiotherapy
16%
Randomized Controlled Trial
8%
Randomized Phase III Trial
6%
Recurrent Prostate Cancer
6%
Risk Prediction Model
6%
Risk Stratification
6%
Specific Treatment
6%
Threatened Preterm Birth
6%
Threatened Preterm Labor
26%
Timing of Antenatal Corticosteroids
6%
